Marshall Wace, LLP Spruce Biosciences, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.7 - $5.49 $23,433 - $183,783	-33,476 Reduced 31.66%	72,245 $57,000
Q4 2023 Feb 14, 2024	BUY	$1.04 - $2.93 $109,949 - $309,762	105,721 New	105,721 $309,000
Q1 2021 May 17, 2021	SELL	$14.8 - $25.79 $205,009 - $357,243	-13,852 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.38 - $32.42 $213,043 - $449,081	13,852 New	13,852 $337,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.42M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.